SCHEMBL1967320

SCHEMBL1967320

CC(C)Oc1ccc(-c2noc(-c3ccc(NC(=O)c4ccncc4)cc3)n2)cc1Cl

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.69
LMNA P02545 5/20 0.69
MEN1 O00255 4/20 0.69
KMT2A Q03164 4/20 0.69
HPGD P15428 3/20 0.69
NPSR1 Q6W5P4 2/20 0.69
HTT P42858 4/20 0.67
MAPK1 P28482 2/20 0.67
L3MBTL1 Q9Y468 1/20 0.67
ALOX15 P16050 1/20 0.63
CASP1 P29466 1/20 0.63
CASP7 P55210 1/20 0.63
HSD17B10 Q99714 1/20 0.63
MAP4K4 O95819 3/20 0.61
MINK1 Q8N4C8 3/20 0.61
DYRK3 O43781 1/20 0.61
MARK3 P27448 1/20 0.61
PLK1 P53350 1/20 0.61
MAP4K5 Q9Y4K4 1/20 0.61
POLB P06746 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3740117 0.86 MAP4K4 (0.64) SMN1; SMN2HPGDHSD17B10MAP4K4MINK1
SCHEMBL3740150 0.83 MAP4K4 (0.60) SMN1; SMN2LMNAMEN1KMT2AHPGD
SCHEMBL12582033 0.82 MAP4K4 (0.62) MAP4K4MINK1DYRK3MARK3PLK1
SCHEMBL3746333 0.81 MAP4K4 (0.63) MAP4K4MINK1DYRK3MARK3PLK1
SCHEMBL3741047 0.81 S1PR1 (0.73) MAP4K4MINK1DYRK3MARK3PLK1
SCHEMBL1966022 0.79 S1PR1 (0.63) MAP4K4MINK1DYRK3MARK3PLK1
SCHEMBL3741171 0.79 MAP4K4 (0.65) MAP4K4MINK1DYRK3MARK3PLK1
SCHEMBL12162495 0.78 MAP4K4 (0.56) MAP4K4MINK1DYRK3MARK3PLK1
SCHEMBL1964676 0.78 MAP4K4 (0.88) MAP4K4MINK1DYRK3MARK3PLK1
SCHEMBL1965821 0.78 MAP4K4 (0.61) MAP4K4MINK1DYRK3MARK3PLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2509424-A1 NOVEL OXADIAZOLE COMPOUNDS Abbott Laboratories (US) 2012-10-17 EP claimed
US-20110207704-A1 Novel Oxadiazole Compounds ABBOTT LABORATORIES (US) 2011-08-25 US claimed
WO-2011071570-A1 NOVEL OXADIAZOLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-16 WO claimed
EP-2509424-A1 NOVEL OXADIAZOLE COMPOUNDS Abbott Laboratories (US) 2012-10-17 EP disclosed
US-20110207704-A1 Novel Oxadiazole Compounds ABBOTT LABORATORIES (US) 2011-08-25 US disclosed
US-20110207704-A1 Novel Oxadiazole Compounds ABBOTT LABORATORIES (US) 2011-08-25 US disclosed
US-20110207704-A1 Novel Oxadiazole Compounds ABBOTT LABORATORIES (US) 2011-08-25 US disclosed
WO-2011071570-A1 NOVEL OXADIAZOLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-16 WO disclosed
WO-2011071570-A1 NOVEL OXADIAZOLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207704-A1 Novel Oxadiazole Compounds S1PR3, S1PR1, S1PR2 SMN1; SMN2 3564/4885LMNA 4756/4885MEN1 2929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.